Major depression and the synthetic enhancer substances, (−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane

@article{Gaszner2006MajorDA,
  title={Major depression and the synthetic enhancer substances, (−)-deprenyl and R-(−)-1-(benzofuran-2-yl)-2-propylaminopentane},
  author={P{\'e}ter Gaszner and Ildikó Miklya},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2006},
  volume={30},
  pages={5-14}
}
  • P. Gaszner, I. Miklya
  • Published 31 January 2006
  • Biology, Chemistry
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
Neuroprotective and Antioxidant Effects of Novel Benzofuran-2-Carboxamide Derivatives
TLDR
The structure-activity relationship studies suggest that the compound with -CH3 substitution at R2 and -OH substituted at R3 positions of the benzofuran moiety might serve as the lead exhibiting potent anti-excitotoxic, ROS scavenging, and antioxidant activities.
Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma
TLDR
BPAP treatment had a beneficial effect on bodyweight suggesting that the compound at least in part is able to compensate the cancer-related wasting, and the low toxicity and confirmed antitumor effect of BPAP against experimental lung adenocarcinoma deserves further attention.
The Knoll-Concept to Decrease the Prevalence of Parkinson’s Disease
TLDR
D, registered at present in 64 countries, started its world-wide carrier as a therapeutic agent in 1977 as the unique MAO inhibitor free of the cheese-effect, and became famous in 1971/1972 as the first selective inhibitor of B-type monoamine oxidase (MAO-B) (Knoll  Magyar, 1972).
Low COMT and Stress Potentiate Functional Pain and Depressive Behavior, Especially in Female Mice.
TLDR
The results suggest that genetic and environmental factors that enhance catecholamine bioavailability cause abnormalities in BDNF signaling and increase risk of comorbid functional pain and depression, especially among females.
Antidepressants for smoking cessation.
TLDR
Bupropion and nortriptyline appear to be equally effective and of similar efficacy to NRT, and high quality evidence that bupropion significantly increased long-term cessation when used as the sole pharmacotherapy is found.
Analysis and Supplement with the Mechanism of Electrosynthesizing Benzofurnan Derivatives
Davood Nematollahi et al. have successfully electrosynthesised a series of benzofuran derivatives in the presence of nucleophile agents. Base on their experimental result, we analyzed the electron
...
...

References

SHOWING 1-10 OF 48 REFERENCES
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
  • J. Knoll
  • Biology, Psychology
    Pharmacology & toxicology
  • 1998
TLDR
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.
Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
  • J. Knoll, I. Miklya
  • Biology, Chemistry
    Archives internationales de pharmacodynamie et de therapie
  • 1994
TLDR
The results prove that the described effects of deprenyl are unrelated to MAO-B inhibition and indicate the existence of hitherto unknown catecholaminergic and serotoninergic activity enhancer mechanisms in the brain, of which the former is stimulated and the latter inhibited by multiple, small dose administrations ofdeprenyl and related substances.
The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.
TLDR
1-phenyl-2-propylaminopentane facilitates learning and retention, is highly potent in antagonizing the tetrabenazine-induced depression in behavioral tests and is very effective in the forced swimming test.
The possible mechanisms of action of (-)deprenyl in Parkinson's disease
  • J. Knoll
  • Biology, Chemistry
    Journal of Neural Transmission
  • 2005
TLDR
The advantage of the combination of levodopa and (-)deprenyl in the treatment of Parkinson's disease was summarized as follows.
R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
  • J. Knoll
  • Biology, Chemistry
    Journal of neural transmission. Supplementum
  • 1987
(-)Deprenyl, when administered continuously in small doses (0.25 mg/kg/day), facilitates the activity of the nigrostriatal dopaminergic neuron because of its highly characteristic complex spectrum of
...
...